A presentation on thimerosal, a mercury-based vaccine preservative, set to be delivered to the CDC’s advisory committee has come under scrutiny for referencing a non-existent study. The report, “Thimerosal as a Vaccine Preservative,” authored by Lyn Redwood—former leader of the anti-vaccine group Children’s Health Defense—cited a 2008 study allegedly co-authored by UC Davis Professor Emeritus Robert Berman. However, Berman confirmed that such a study was never conducted by him and said the cited findings misrepresented his actual research published in Toxicological Sciences.
The erroneous citation was first reported by Reuters, prompting the CDC to upload a revised version of Redwood’s presentation, removing the disputed slide. The controversy has intensified after Health Secretary Robert F. Kennedy Jr. recently replaced the CDC’s entire 17-member vaccine panel with eight new members, half of whom are known vaccine skeptics.
Both Republican Senator Bill Cassidy and Democratic Senator Patty Murray have urged postponement of the June 25–26 meeting, citing the panel’s lack of vetting and the absence of a CDC director. Redwood’s presentation contrasts with a separate CDC staff report reaffirming that thimerosal-containing vaccines do not cause autism or other neurodevelopmental issues.
According to CDC data, 96% of flu vaccines administered during the 2024–25 season were thimerosal-free, and only 0.3% of flu vaccines given to pregnant women contained the preservative. Kennedy, a long-time critic of vaccine safety, has previously claimed thimerosal causes brain damage—claims consistently debunked by scientific research.
The thimerosal debate highlights rising tensions around vaccine policy and misinformation, especially as newly appointed CDC advisors consider whether to recommend thimerosal-free vaccines for all pregnant women and children. Redwood has not yet responded to requests for comment.


Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales
Pentagon Ends Military Education Programs With Harvard University
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Newly Released DOJ Epstein Files Expose High-Profile Connections Across Politics and Business
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran 



